Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® Cdiff Test to detect Clostridium difficile (C. difficile) ...

This is a preview. Log in through your library . Abstract Polymerase chain reaction (PCR) amplification of a segment of the toxin A gene was used to detect toxigenic Clostridium difficile directly ...

This is a preview. Log in through your library . Abstract Background. Clostridium difficile-associated diarrhea (CDAD) is the major cause of health care-associated infectious diarrhea. Current ...

Infection with the pathogen Clostridium difficile is a significant source of healthcare-associated infections and estimated to account for 12 percent of all HAIs in the U.S.1 C. diff infection is the ...

A single Clostridium difficile infection presents an array of challenges for hospitals. A December 2015 study in the American Journal of Infection Control found C. difficile infections can increase ...

Please provide your email address to receive an email when new articles are posted on . GenePOC Inc. has announced the launch and FDA clearance of its Clostridium difficile molecular test, GenePOC ...

A stool test is a diagnostic procedure that involves analyzing fecal matter, or poop, to check for signs of infection, inflammation, or disease. The specific analysis depends on a person’s symptoms ...

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the ...

A pilot study by Massachusetts General Hospital (MGH) investigators may lead to greater availability and acceptability of an unusual treatment for a serious medical problem – use of fecal material ...

For patients with the difficult-to-treat intestinal infection caused by a bacterium called Clostridium difficile, a "poop transplant" that uses frozen poop may be as effective as one that uses fresh ...